Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens

BACKGROUND: During stavudine phase-out plan in developing countries, tenofovir is used to substitute stavudine. However, knowledge regarding whether there is any difference of the frequency of renal injury between tenofovir/lamivudine/efavirenz and tenofovir/lamivudine/nevirapine is lacking. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Manosuthi, Weerawat, Mankatitham, Wiroj, Lueangniyomkul, Aroon, Prasithsirikul, Wisit, Tantanathip, Preecha, Suntisuklappon, Busakorn, Narkksoksung, Anongnuch, Nilkamhang, Samruay, Sungkanuparph, Somnuek
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020664/
https://www.ncbi.nlm.nih.gov/pubmed/20937122
http://dx.doi.org/10.1186/1742-6405-7-37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020664/
https://www.ncbi.nlm.nih.gov/pubmed/20937122
http://dx.doi.org/10.1186/1742-6405-7-37

Ejemplares similares